Table 3.
Univariate and multivariate analysis of overall survival.
| Factors | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| P-value | HR (95% CI) | P-value | HR(95% CI) | |
| Sex: Male or female | 0.256 | 0.845 (0.632-1.130) | ||
| Age: <45 years or ≥45 years | 0.385 | 1.094 (0.894-1.338) | ||
| Metastasis at presentation: Present or absent | 0.523 | 1.074 (0.862-1.338) | ||
| Liver metastasis: Present or absent | 0.995 | 1.001 (0.736-1.361) | ||
| Lung metastasis: Present or absent | 0.894 | 0.980 (0.724-1.325) | ||
| Pre-treatment S-ALP level: Normal or elevated | <0.001 | 1.794 (1.453-2.214) | <0.001 | 1.794 (1.462-2.201) |
| Post-treatment S-ALP level: Normal or elevated | <0.001 | 2.777 (2.195-3.514) | <0.001 | 2.657 (2.122-3.327) |
| Number of drugs for chemotherapy: Two or three | 0.881 | 1.017 (0.820-1.261) | ||
| Number of involved sites: 1 or ≥1 | 0.811 | 0.954 (0.645-1.409) | ||
| Vertebral metastasis: Present or absent | 0.069 | 1.210 (0.985-1.486) | ||
| Skeletal-related events: Present or absent | 0.657 | 0.933 (0.688-1.265) | ||
HR: hazard ratio; 95% CI: 95% confidence interval.